CA3245376A1 - INSULIN-BASED FUSION PROTEIN - Google Patents
INSULIN-BASED FUSION PROTEINInfo
- Publication number
- CA3245376A1 CA3245376A1 CA3245376A CA3245376A CA3245376A1 CA 3245376 A1 CA3245376 A1 CA 3245376A1 CA 3245376 A CA3245376 A CA 3245376A CA 3245376 A CA3245376 A CA 3245376A CA 3245376 A1 CA3245376 A1 CA 3245376A1
- Authority
- CA
- Canada
- Prior art keywords
- fusion protein
- proinsulin
- canine
- sequence
- feline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315296P | 2022-03-01 | 2022-03-01 | |
| US63/315,296 | 2022-03-01 | ||
| PCT/US2023/063510 WO2023168288A2 (en) | 2022-03-01 | 2023-03-01 | Insulin fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3245376A1 true CA3245376A1 (en) | 2023-09-07 |
Family
ID=87884362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3245376A Pending CA3245376A1 (en) | 2022-03-01 | 2023-03-01 | INSULIN-BASED FUSION PROTEIN |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250188144A1 (https=) |
| EP (1) | EP4486796A4 (https=) |
| JP (1) | JP2025507929A (https=) |
| KR (1) | KR20240167718A (https=) |
| CN (1) | CN119562965A (https=) |
| AU (1) | AU2023228668A1 (https=) |
| CA (1) | CA3245376A1 (https=) |
| CL (1) | CL2024002605A1 (https=) |
| IL (1) | IL315354A (https=) |
| MX (1) | MX2024010693A (https=) |
| WO (1) | WO2023168288A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120173090B (zh) * | 2025-05-21 | 2025-07-29 | 华中农业大学 | 猫血清白蛋白突变体、及其cho细胞表达方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US9505823B2 (en) * | 2006-08-07 | 2016-11-29 | TEV A Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
| CA2676932C (en) * | 2007-02-01 | 2015-11-24 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| BR112014015156A2 (pt) * | 2011-12-20 | 2020-10-27 | Indiana University Research And Technology Corporation | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira |
| WO2022098906A1 (en) * | 2020-11-04 | 2022-05-12 | The Trustees Of The University Of Pennsylvania | Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs |
| AU2023228669A1 (en) * | 2022-03-01 | 2024-09-19 | Scout Bio, Inc. | Viral vector genome encoding an insulin fusion protein |
-
2023
- 2023-03-01 KR KR1020247029510A patent/KR20240167718A/ko active Pending
- 2023-03-01 AU AU2023228668A patent/AU2023228668A1/en active Pending
- 2023-03-01 IL IL315354A patent/IL315354A/en unknown
- 2023-03-01 WO PCT/US2023/063510 patent/WO2023168288A2/en not_active Ceased
- 2023-03-01 JP JP2024552283A patent/JP2025507929A/ja active Pending
- 2023-03-01 US US18/843,112 patent/US20250188144A1/en active Pending
- 2023-03-01 CN CN202380034373.8A patent/CN119562965A/zh active Pending
- 2023-03-01 EP EP23764094.1A patent/EP4486796A4/en active Pending
- 2023-03-01 CA CA3245376A patent/CA3245376A1/en active Pending
-
2024
- 2024-08-30 MX MX2024010693A patent/MX2024010693A/es unknown
- 2024-08-30 CL CL2024002605A patent/CL2024002605A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025507929A (ja) | 2025-03-21 |
| US20250188144A1 (en) | 2025-06-12 |
| KR20240167718A (ko) | 2024-11-27 |
| WO2023168288A2 (en) | 2023-09-07 |
| AU2023228668A1 (en) | 2024-09-19 |
| WO2023168288A3 (en) | 2023-09-28 |
| MX2024010693A (es) | 2024-12-06 |
| EP4486796A4 (en) | 2026-03-04 |
| IL315354A (en) | 2024-11-01 |
| CN119562965A (zh) | 2025-03-04 |
| EP4486796A2 (en) | 2025-01-08 |
| CL2024002605A1 (es) | 2025-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6978407B2 (ja) | Ｇｌｐ−１及び代謝性疾患を治療するための組成物におけるその使用 | |
| US20230405150A1 (en) | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines | |
| US20250388926A1 (en) | Viral vector genome encoding an insulin fusion protein | |
| US10736970B2 (en) | Polypeptide complex of titin-telethonin beta-pleated sheet structure as polypeptide drug carrier, method of using the polypeptide complex, and fusion protein complex thereof | |
| US20250188144A1 (en) | Insulin fusion protein | |
| US20230372539A1 (en) | Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases | |
| US20250171515A1 (en) | Aav vectors for delivery of glp-1 receptor agonist fusions | |
| CN116376921A (zh) | 一种用于治疗糖尿病的aav载体及其用途 | |
| HK40098913B (zh) | 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法 | |
| HK40098913A (zh) | 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法 | |
| HK1045160A (en) | Expression and export of anti-obesity proteins as fc fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240903 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240904 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240904 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240904 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20240904 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250220 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |